ArticleTranslational cancer research2025
Comprehensive analysis of gene signature linking hypoxia and lactylation for predicting prognosis and immunotherapy response in patients with gastric cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is the fifth most commonly diagnosed cancer worldwide and ranks as the third leading cause of cancer-related deaths. In the tumor microenvironment (TME), malignant cells undergo hypoxic adaptation via metabolic reprogramming, which promotes cellular proliferation and lactate accumulation. However, the significance of hypoxia- and lactylation-related genes (HALRGs) in GC remains unclear. This study aimed to investigate the impact of hypoxia and lactylation on GC and to construct relevant prognostic models. Methods: We downloaded single-cell RNA sequencing (scRNA-seq), spatial transcriptome (ST) data, and clinical data. The least absolute shrinkage and selection operator (LASSO) algorithm was used to develop a prognostic model, which was validated in an external cohort. Immune cell infiltration was analyzed using the CIBERSORT algorithm, while the Tumor Immune Dysfunction and Exclusion (TIDE) score and ESTIMATE method were combined to evaluate the prognostic potential of immunotherapy response. Results: We analyzed 23,447 genes and 104,150 cells from scRNA-seq, classifying the cells into seven distinct types. The spatial distribution characteristics of these cell types were further examined using ST data. Inference of copy number variations (InferCNV) analysis was performed on epithelial cells to differentiate between malignant and normal cells, revealing that normal epithelial cells could be further categorized into five subtypes. We then developed a prognostic model based on HALRGs using The Cancer Genome Atlas (TCGA) data, which was validated in the Gene Expression Omnibus (GEO) dataset. Patients were divided into high- and low-risk groups according to HALRG scores. Interestingly, the high-risk group exhibited higher TIDE scores, suggesting a poorer response to immunotherapy. Conclusions: This study uncovered the cellular heterogeneity of GC by integrating scRNA-seq and ST data. The results demonstrated that the HALRG risk model may be effective in predicting the clinical prognosis and has the potential to guide personalized treatment in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.